Sun Pharma Advanced Research Company · NSE: SPARC · BSE: 532872
Q3 FY19 results · Oct–Dec 2018
Sun Pharma Advanced Research Company reported revenue from operations of ₹19.88 crore and net loss of ₹69.02 crore for Q3 FY19 (Oct–Dec 2018), on a standalone basis.
| Item | Q3 FY19 | Q3 FY18 | YoY | Q2 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 19.88 | — | — | 61.35 | −67.6% |
| Other income | 3.28 | — | — | 4.57 | −28.2% |
| Total income | 23.16 | — | — | 65.92 | −64.9% |
| Profit before tax | (69.02) | — | — | (2.58) | Loss widened |
| Net profit for the period | (69.02) | — | — | (2.58) | Loss widened |
| EPS, basic (₹) | (2.72) | — | — | (0.10) | not comparable |
| Net margin (%) | -347.2 | — | -4.2 |
Standalone
- Filed with BSE
- 05 Feb 2019, 14:33 IST
- Board meeting
- 04 Feb 2019
- Period
- 01 Oct 2018 to 31 Dec 2018
- Review status
- Unaudited
- Source
- XBRL filing on BSE